Main Menu
Menu

News

Publish Date
Drug Pricing, Overreach Dominate IP Disclaimer Feedback
  • Law360
  • Dani Kass
FTC Backs USPTO Terminal Disclaimer NPRM as Others Warn it Exceeds Agency Authority
  • IPWatchdog
  • Eileen McDermott
USPTO’s AI-Assisted Inventions Guidance Irks ABA IP Section
  • Law360
  • Hannah Albarazi
Patent Owners, Challengers Spar Over PTAB Rule Proposal
  • Law360
  • Ryan Davis
USPTO Hears Array Of Ideas For Altering Director Review
  • Law360
  • Ryan Davis
USPTO Extends Deadline for AI Inventorship Comments as Some Criticize Pannu Factors
  • IPWatchdog
  • Steve Brachmann
Organizations Tell USPTO Proposed 2025 Fees ‘Misuse’ Office’s Fee Setting Authority
  • IPWatchdog
  • Eileen McDermott
As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’
  • PharmaVoice
  • Michael Gibney
Former USPTO Officials Urge Vidal to Immediately Withdraw NPRM on Terminal Disclaimers
  • IPWatchdog
  • Steve Brachmann
Ex-USPTO Directors Want Vidal To Withdraw Disclaimer Plans
  • Law360
  • Hailey Konnath
Quintet of Ex-Patent Office Officials Slam Proposed Rulemaking
  • Bloomberg Law
  • Michael Shapiro
C4IP Urges Senate Judiciary to Ignore Common Myths About Drug Patents
  • IPWatchdog
  • Steve Brachmann
Scroll to Top